Forte Biosciences, Inc. (FBRX)
76.99
0.00 (0.00%)
USD |
NASDAQ |
Sep 01, 16:00
Forte Biosciences Research and Development Expense (TTM) : 79.74M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 79.74M |
| March 31, 2026 | 66.02M |
| December 31, 2025 | 58.25M |
| September 30, 2025 | 41.74M |
| June 30, 2025 | 32.41M |
| March 31, 2025 | 29.53M |
| December 31, 2024 | 21.19M |
| September 30, 2024 | 19.53M |
| June 30, 2024 | 20.03M |
| March 31, 2024 | 21.43M |
| December 31, 2023 | 21.86M |
| September 30, 2023 | 20.78M |
| June 30, 2023 | 15.79M |
| March 31, 2023 | 9.688M |
| December 31, 2022 | 5.594M |
| September 30, 2022 | 4.458M |
| June 30, 2022 | 8.726M |
| March 31, 2022 | 11.20M |
| December 31, 2021 | 13.82M |
| Date | Value |
|---|---|
| September 30, 2021 | 15.48M |
| June 30, 2021 | 13.50M |
| March 31, 2021 | 11.93M |
| December 31, 2020 | 9.964M |
| September 30, 2020 | 8.111M |
| June 30, 2020 | 4.789M |
| March 31, 2020 | 3.162M |
| December 31, 2019 | 14.04M |
| September 30, 2019 | 28.30M |
| June 30, 2019 | 40.01M |
| March 31, 2019 | 52.33M |
| December 31, 2018 | 50.55M |
| September 30, 2018 | 43.43M |
| June 30, 2018 | 38.93M |
| March 31, 2018 | 32.92M |
| December 31, 2017 | 29.11M |
| September 30, 2017 | 27.35M |
| June 30, 2017 | 26.26M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| argenx SE | 1.640B |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Anika Therapeutics, Inc. | 27.45M |
| Savara, Inc. | 86.84M |